Literature DB >> 9933788

Vascular endothelial growth factor: an important angiogenic mediator in bladder cancer.

J P Crew1.   

Abstract

Angiogenesis is the growth of new blood vessels from existing ones and is critical for tumour development, invasion and metastasis. In bladder cancer the prognostic significance of mean vascular density, a surrogate for angiogenesis, has lead to study of the factors determining the angiogenic phenotype. The motivation for these studies has been the search for non-invasive prognostic or diagnostic markers for the disease and for new therapeutic strategies against bladder cancer recurrence and progression. Whilst a large number of factors are involved in the mediation of tumour angiogenesis, vascular endothelial growth factor (VEGF) is widely considered to be central to the process. This review highlights the information presently available regarding the role of VEGF in bladder cancer through observational studies of its expression in bladder tumours and within the urine. In addition the value of VEGF in determining the prognosis in bladder cancer and the future possibilities for anti-VEGF therapy are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9933788     DOI: 10.1159/000019811

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  12 in total

Review 1.  Imaging angiogenesis of genitourinary tumors.

Authors:  Ying-Kiat Zee; James P B O'Connor; Geoff J M Parker; Alan Jackson; Andrew R Clamp; M Ben Taylor; Noel W Clarke; Gordon C Jayson
Journal:  Nat Rev Urol       Date:  2010-01-19       Impact factor: 14.432

2.  Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma.

Authors:  Shuzhe Yang; Xiaohou Wu; Chunli Luo; Cuicui Pan; Jun Pu
Journal:  World J Urol       Date:  2010-07-01       Impact factor: 4.226

3.  Significance of angiogenesis and microvascular invasion in renal cell carcinoma.

Authors:  Yoram Dekel; Rumelia Koren; Valentina Kugel; Pinhas M Livne; Rivka Gal
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

Review 4.  Management of bladder cancer: current and emerging strategies.

Authors:  Neeraj Agarwal; Maha Hussain
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

5.  Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?

Authors:  Wassim Kassouf; Gordon A Brown; Peter C Black; Mark B Fisher; Teruo Inamoto; Tony Luongo; David Gallagher; Menashe Bar-Eli; David J McConkey; Liana Adam; Colin P N Dinney
Journal:  J Urol       Date:  2008-07-18       Impact factor: 7.450

6.  Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases.

Authors:  Ala'eddin Jebreel; James England; Karen Bedford; Justin Murphy; Laszlo Karsai; Stephen Atkin
Journal:  Int J Exp Pathol       Date:  2007-08       Impact factor: 1.925

7.  Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer.

Authors:  Michio Kosugi; Akira Miyajima; Eiji Kikuchi; Takeo Kosaka; Yutaka Horiguchi; Masaru Murai
Journal:  Hum Cell       Date:  2007-02       Impact factor: 4.174

Review 8.  [Urine-based markers of angiogenesis in bladder cancer].

Authors:  M Becker; D Tilki; T Szarvas; H Rübben; S Ergün
Journal:  Urologe A       Date:  2009-06       Impact factor: 0.639

Review 9.  Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.

Authors:  Guillaume Grisay; Julien Pierrard; Caterina Confente; Emmanuel Seront
Journal:  Curr Treat Options Oncol       Date:  2020-12-02

Review 10.  The Interplay between Oxidative Stress, Inflammation and Angiogenesis in Bladder Cancer Development.

Authors:  Paulina Wigner; Radosław Grębowski; Michał Bijak; Joanna Saluk-Bijak; Janusz Szemraj
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.